¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cutaneous subacute lupus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cutaneous helminthiasis
    ÇǺο¬ÃæÁõ
  • cutaneous horn
    ÇǺλÔ
  • cutaneous larva migrans
    ÇǺξֹú·¹ÀÌÇàÁõ, ÇǺÎÀ¯ÃæÀÌÇàÁõ
  • cutaneous leishmaniasis
    ÇǺθ®½´¸¸Æí¸ðÃæÁõ
  • cutaneous lymphoid hyperplasia
    ÇǺθ²ÇÁ°ú´ÙÇü¼º
  • cutaneous mucosal hyalinosis
    ÇǺÎÁ¡¸·À¯¸®ÁúÁõ
  • cutaneous necrotizing venulitis
    ÇǺα«»ç¼¼Á¤¸Æ¿°
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cutaneous nerve
    ÇǺνŰæ
  • cutaneous nerve ending
    ÇǺνŰæÁ¾¸»
  • cutaneous nerve somatosensory evoked potential
    ÇǺνŰæ¸ö°¨°¢À¯¹ßÀüÀ§
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous ridge
    ÇǺδɼ±
  • cutaneous sarcoidosis
    ÇǺλ縣ÄÚÀ̵åÁõ
  • cutaneous schistosomiasis
    ÇǺÎÁÖÇ÷ÈíÃæÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cutaneous gangrene
    ÇǺα«Àú
  • cutaneous habronemiasis
    ÇǺÎÇϺê·Î³×¸¶Áõ
  • cutaneous hallucination
    ÇǺÎȯ°¢
  • cutaneous helminthiasis
    ÇǺο¬ÃæÁõ
  • cutaneous horn
    ÇǺλÔ
  • cutaneous leishmaniasis
    ÇǺθ®½´¸¸Æí¸ðÃæÁõ
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cutaneous nerve
    ÇǺνŰæ
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous ridge
    ÇǺδɼ±
  • cutaneous sarcoidosis
    ÇǺλ縣ÄÚÀ̵åÁõ
  • cutaneous schistosomiasis
    ÇǺÎÁÖÇ÷ÈíÃæÁõ
  • cutaneous sensation
    ÇǺΰ¨°¢
  • cutaneous sulcus
    ÇǺΰí¶û
  • cutaneous symptom
    ÇǺÎÁõ»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • subacute migratory nodular panniculitis
    ¾Æ±Þ¼º À̵¿¼º °áÀý Áö¹æÃþ¿°
  • subacute myelo optico neuropathy
    ¾Æ±Þ¼º ô¼ö½Ã½Å°æÀå¾Ö(¡­ô±âÐãÊãêÌèî¡äô)
  • subacute myelo-optic neuropathy
    ¾Æ±Þ¼ºÃ´¼ö½Ã½Å°æº´Áõ(¡­ô±âÐãÊãêÌèî¡äô ).
  • subacute myopathy
    ¾Æ±Þ¼º ±Ùº´Áõ(¡­ÐÉÜ»ñø).
  • subacute necrotizing encephalomyelopathy
    ¾Æ±Þ¼º ±«»ç¼º ³úô¼öº´Áõ(¡­ÎÕÞÝàõÒàô±âÐÜ»ñø).
  • subacute necrotizing encephalomyelopathy
    ¾Æ±Þ¼º ±«»ç¼º ³úô¼öº´Áõ(¡­ÎÕÞÝàõÒàô±âÐÜ»ñø)
  • subacute necrotizing encephalopathy
    ¾Æ±Þ¼º ±«»ç¼º ³úº´Áõ.
  • subacute necrotizing encephalopathy
    ¾Æ±Þ¼º ±«»ç¼º ³úº´Áõ(¡­ÒàÜ»ñø)
  • subacute necrotizing myelitis
    ¾Æ±Þ¼º ±«»ç¼º ô¼ö¿°(¡­ô±âÐæú)
  • subacute sclerosing encephalitis
    ¾Æ±Þ¼º °æÈ­¼º ³ú¿°(¡­ÌãûùàõÒàæú)
  • subacute sclerosing panencephalitis
    ¾Æ±Þ¼º °æÈ­¼º ¹ü³ú¿°
  • subacute sclerosing panencephalitis
    ¾Æ±Þ¼º °æÈ­¼º ¹ü³ú¿°(¡­ÛñÒàæú)
  • subacute sclerosing panencephalitis (SSPE)
    ¾Æ±Þ¼º °æÈ­¼º¹ü³ú¿°
  • subacute sclerotic leukoencephalitis
    ¾Æ±Þ¼º °æÈ­¼º ¹éÁú³ú¿°(ÛÜòõÒàæú)
  • subacute sensorimotor paralysis
    ¾Æ±Þ¼º Áö°¢¿îµ¿¼º ¸¶ºñ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Cutaneous part
    ÇǺκκÐ
    [¿¾ ¿ë¾î] ÇǺκÎ
  • Cutaneous region
    ÇǺκÎÀ§
    [¿¾ ¿ë¾î] ÇǺκÎ
  • Cutaneous gland
    ÇǺλù
    [¿¾ ¿ë¾î] ÇǺμ±
  • Cutaneous nerve terminal
    ÇǺνŰæÁ¾¸» (¢Ñ ½Å°æÁ¾¸»)
    [¿¾ ¿ë¾î] ÇǺνŰæÁ¾¸»
  • Cutaneous vein
    ÇǺÎÁ¤¸Æ
    [¿¾ ¿ë¾î] ÇÇÁ¤¸Æ
  • Cutaneous layer
    ÇǺÎÃþ
    [¿¾ ¿ë¾î] ÇǺÎÃþ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SAT saliva alcohol test; satellite; serum antitrypsin; single-agent chemotherapy; slide agglutination te...
SBE breast self-examination; short below-elbow [cast]; shortness of breath on exertion; small bowel enem...
SDC serum digoxin concentration; Smith delay compensator; sodium deoxycholate; subacute combined degener...
SHN spontaneous hemorrhagic necrosis; subacute hepatic necrosis
SIA serum inhibitory activity; stress-induced analgesia; stress-induced anesthesia; subacute infectious ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DLE Discoid Lupus Erythematosus
LAC Lupus AntiCoagulant
LA lupus anticoagulans
LE Lupus Erythematosus
LN Lupus Nephritis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cutaneous gland
    ÇǺΠ¼±
  • cutaneous hyperactivity
    ÇǺΠ°ú¹Î ¹ÝÀÀ
  • cutaneous hypersensitivity
    ÇǺΠ°ú¹ÎÁõ
  • cutaneous lymphoblastoma
    ÇǺΠ¸²ÇÁ¾Æ¼¼Æ÷Á¾
  • cutaneous manifestation
    ÇǺΠÁõ»ó ¹× ¡ÈÄ
  • cutaneous metastatic carcinoma
    ÇǺΠÀüÀÌ ¾Ï, ÇǺΠÀüÀÌ ¾ÏÁ¾
  • cutaneous myxoid cyst
    ÇǺΠÁ¡¾×¾ç ³¶Á¾
  • cutaneous nerve
    ÇǺΠ½Å°æ, ÇÇ ½Å°æ
  • cutaneous nociceptor
    ÇÇºÎ Ä§ÇØ ¼ö¿ëü, ÇǺΠÀ¯ÇØ ¼ö¿ë±â
  • cutaneous part
    ÇǺΠÆí
  • cutaneous polymodal nociceptor
    ÇǺΠ´ÙÇü Ä§ÇØ ¼ö¿ëü, ÇǺΠ´ÙÇü À¯ÇØ ¼ö¿ë±â
  • cutaneous pseudolymphoma
    ÇǺΠ°¡¼º ¸²ÇÁÁ¾
  • cutaneous reaction
    ÇǺΠ¹ÝÀÀ
  • cutaneous region
    ÇǺΠºÎÀ§
  • cutaneous spot
    ÇǺΠ¹Ý, ÇǺΠ¹ÝÁ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lupus A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis.
(27 Sep 1997)
lupus anticoagulant An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus.
(27 Sep 1997)
lupus anticoagulants Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT).
Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area.
See also cardiolipin antibodies and phospholipid antibodies.
(05 Mar 2000)
lupus band test A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell <pathology> Phagocyte that has ingested nuclear material of another cell: characteristic of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell test <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result.
(27 Sep 1997)
lupus erythematosus, discoid A chronic form of cutaneous lupus erythematosus (lupus erythematosus, cutaneous) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterised by the presence of discoid skin plaques showing varying degrees of oedema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
(12 Dec 1998)
lupus erythematosus profundus A subcutaneous panniculitis with marked lymphocyte infiltration of fat lobules giving rise to deep-seated, firm, rubbery nodules that sometimes become ulcerated, usually of the face; may occur in systemic and localised lupus erythematosus.
Synonym: lupus profundus.
(05 Mar 2000)
lupus erythematosus, systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterised principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown aetiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of le cells in the blood or bone marrow.
(12 Dec 1998)
lupus erythematosus test <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result.
(27 Sep 1997)
lupus glomerulonephritis-pathology Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN.
(05 Mar 2000)
lupus-like syndrome <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á